On Wednesday, Mankind Pharma said that it has agreed with Dr Reddy’s Laboratories (DRL) to acquire two of its brands – one asthma and one infant care brand. The deal size was not disclosed.

• Hindustan Copper Reports 9% Rise in MIC Output for FY26
• SAIL Shares Slip 0.91% as CMD Amarendu Prakash Steps Down
• Bosch Jumps 12% in Two Sessions on E-Mobility JV
• Latent View Analytics Shares Skyrocket 20% on Deal with Healtheon AI 
• Ola Electric Shares Jump 9% on Roadster X+ Price Cut

Combihale, a drug used for treating asthma and chronic obstructive pulmonary disease, has a category market size of Rs 900 crore, growing at 14 per cent (IQVIA). Daffy, a soap-free moisturizing bar for infants, operates in a market category valued at Rs 1000 crore and is growing at 18 per cent (IQVIA).

The company said that the acquisition of Combihale is expected to strengthen Mankind’s presence in the inhalation respiratory market segment.